Clinical Trial Update: RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating ramucirumab with nab-paclitaxel and gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Hellenic Cooperative Oncology Group | Conditions: Pancreatic Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED